United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Is Immuron (ASX: IMC) quietly staging a turnaround? PROIBS launch sparks 20% rally Immuron (ASX: IMC) shares jumped 20 percent following its IBS product launch. Can the PROIBS rollout turn this microcap into a digestive health contender? byVenkateshOctober 26, 2025